Episode notes
Join host, Carmel Fisher for an exclusive conversation with Christopher Schaber, CEO of Soligenix Inc. (NASDAQ: SNGX), as we explore the company's exciting clinical developments in rare disease therapeutics.
With positive interim results from their extended HyBryte™ treatment study and enrollment now open for both their confirmatory Phase 3 CTCL trial and Phase 2 Behçet's Disease study, Soligenix is advancing multiple promising programs simultaneously.
Schaber discusses the clinical differentiation of HyBryte™, which continues showing improvement even after treatment st ...
Keywords
Capitalmarketsmicrocapscarmel fisherthe harvest podcastthe harvestbiotechbiopharmapharmaceuticalssmall capsharvest communicationscapital marketsdiseaseceo interviewscapital MicrocapStocks rarediseaseHyBryte™ treatmentchris schabersoligenix$SNGXrare disease therapeuticsCTCL TreatmentPhase 2 Behçet's Disease studyinternational expansion strategyclinical differentiationconfirmatory Phase 3phase 3 trials